Abstract
L-Asparaginase (L-ASNase, EC 3.5.1.1) catalyzes the hydrolysis of the non-essential amino acid L-Asn to L-Asp and ammonia and is widely used for the treatment of haematopoetic diseases such as acute lymphoblastic leukaemia (ALL) and lymphomas. Therapeutic forms of L-ASNase come from different biological sources (primarily E. coli and Erwinia chrysanthemi). It is well established that the various preparations have different biochemical pharmacology properties, and different tendency to induce side-effects. This is due to different structural, physicochemical and kinetic properties of L-ASNases from the various biological sources. Understanding these properties of various L-ASNases would allow a better decipherment of their catalytic and therapeutic features, thus enabling more accurate predictions of the behaviour of these enzymes under a variety of therapeutic conditions. In addition, detailed understanding of the catalytic mechanism of L-ASNases might permit the design of new forms of L-ASNases with optimal biochemical properties for clinical applications. In this paper we review the available biochemical and pharmacokinetic information of the therapeutic forms of bacterial L-ASNases, and focus on a detailed description of structure, function and clinical applications of these enzymes.
Keywords: L-Asparaginase, acute lymphoblastic leukemia, catalytic mechanism protein crystallography, protein drug
Current Medicinal Chemistry
Title: Structure-Function Relationships and Clinical Applications of L-Asparaginases
Volume: 17 Issue: 20
Author(s): N.E. Labrou, A.C. Papageorgiou and V.I. Avramis
Affiliation:
Keywords: L-Asparaginase, acute lymphoblastic leukemia, catalytic mechanism protein crystallography, protein drug
Abstract: L-Asparaginase (L-ASNase, EC 3.5.1.1) catalyzes the hydrolysis of the non-essential amino acid L-Asn to L-Asp and ammonia and is widely used for the treatment of haematopoetic diseases such as acute lymphoblastic leukaemia (ALL) and lymphomas. Therapeutic forms of L-ASNase come from different biological sources (primarily E. coli and Erwinia chrysanthemi). It is well established that the various preparations have different biochemical pharmacology properties, and different tendency to induce side-effects. This is due to different structural, physicochemical and kinetic properties of L-ASNases from the various biological sources. Understanding these properties of various L-ASNases would allow a better decipherment of their catalytic and therapeutic features, thus enabling more accurate predictions of the behaviour of these enzymes under a variety of therapeutic conditions. In addition, detailed understanding of the catalytic mechanism of L-ASNases might permit the design of new forms of L-ASNases with optimal biochemical properties for clinical applications. In this paper we review the available biochemical and pharmacokinetic information of the therapeutic forms of bacterial L-ASNases, and focus on a detailed description of structure, function and clinical applications of these enzymes.
Export Options
About this article
Cite this article as:
Labrou N.E., Papageorgiou A.C. and Avramis V.I., Structure-Function Relationships and Clinical Applications of L-Asparaginases, Current Medicinal Chemistry 2010; 17 (20) . https://dx.doi.org/10.2174/092986710791299920
DOI https://dx.doi.org/10.2174/092986710791299920 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Epigenetics and Adult Acute Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Toxicity and Surface Modification of Dendrimers: A Critical Review
Current Drug Delivery Regulation of Cytokine Production by γδ T Cells
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Immunosuppressive Therapy for Myelodysplastic Syndromes
Current Pharmaceutical Design The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Finding Drug Targets Through Analysis of the Platelet Transcriptome
Current Pharmaceutical Design Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy
Current Gene Therapy Quantification of Intracellular Proteins and Monitoring Therapy Using Flow Cytometry
Current Drug Targets AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Synthesis and Antiproliferative Evaluation of Spirothiadiazolopyridazine Derivatives
Letters in Drug Design & Discovery Natural Products Chemistry in Marine Ascidians of the Genus Aplidium
Mini-Reviews in Organic Chemistry Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Precision Mechanics with Multifunctional Tools: How HnRNP K and HnRNPs E1/E2 Contribute to Post-Transcriptional Control of Gene Expression in Hematopoiesis
Current Protein & Peptide Science